Logo image of NXTC

NEXTCURE INC (NXTC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NXTC - US65343E2072 - Common Stock

12.8 USD
-0.19 (-1.46%)
Last: 1/22/2026, 1:41:53 PM
Fundamental Rating

2

Taking everything into account, NXTC scores 2 out of 10 in our fundamental rating. NXTC was compared to 525 industry peers in the Biotechnology industry. The financial health of NXTC is average, but there are quite some concerns on its profitability. NXTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NXTC had negative earnings in the past year.
  • In the past year NXTC has reported a negative cash flow from operations.
  • NXTC had negative earnings in each of the past 5 years.
  • In the past 5 years NXTC always reported negative operating cash flow.
NXTC Yearly Net Income VS EBIT VS OCF VS FCFNXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • NXTC has a Return On Assets of -146.44%. This is amonst the worse of the industry: NXTC underperforms 83.43% of its industry peers.
  • NXTC has a Return On Equity of -245.33%. This is in the lower half of the industry: NXTC underperforms 70.67% of its industry peers.
Industry RankSector Rank
ROA -146.44%
ROE -245.33%
ROIC N/A
ROA(3y)-53.01%
ROA(5y)-39.92%
ROE(3y)-61.74%
ROE(5y)-45.48%
ROIC(3y)N/A
ROIC(5y)N/A
NXTC Yearly ROA, ROE, ROICNXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NXTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTC Yearly Profit, Operating, Gross MarginsNXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, NXTC has more shares outstanding
  • The number of shares outstanding for NXTC has been increased compared to 5 years ago.
  • NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NXTC Yearly Shares OutstandingNXTC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
NXTC Yearly Total Debt VS Total AssetsNXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • NXTC has an Altman-Z score of -18.08. This is a bad value and indicates that NXTC is not financially healthy and even has some risk of bankruptcy.
  • NXTC has a Altman-Z score of -18.08. This is amonst the worse of the industry: NXTC underperforms 81.14% of its industry peers.
  • There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.08
ROIC/WACCN/A
WACCN/A
NXTC Yearly LT Debt VS Equity VS FCFNXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.97 indicates that NXTC has no problem at all paying its short term obligations.
  • The Current ratio of NXTC (2.97) is worse than 64.19% of its industry peers.
  • A Quick Ratio of 2.97 indicates that NXTC has no problem at all paying its short term obligations.
  • NXTC has a Quick ratio of 2.97. This is in the lower half of the industry: NXTC underperforms 61.90% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
NXTC Yearly Current Assets VS Current LiabilitesNXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 3.87% over the past year.
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NXTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.72% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.73%
EPS Next 2Y28.33%
EPS Next 3Y22.78%
EPS Next 5Y13.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NXTC Yearly Revenue VS EstimatesNXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 10M 20M 30M 40M
NXTC Yearly EPS VS EstimatesNXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • NXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NXTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTC Price Earnings VS Forward Price EarningsNXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXTC Per share dataNXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • NXTC's earnings are expected to grow with 22.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.33%
EPS Next 3Y22.78%

More info and screens

0

5. Dividend

5.1 Amount

  • NXTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NEXTCURE INC

NASDAQ:NXTC (1/22/2026, 1:41:53 PM)

12.8

-0.19 (-1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-04
Inst Owners32.85%
Inst Owner Change0%
Ins Owners1.53%
Ins Owner Change0%
Market Cap34.30M
Revenue(TTM)N/A
Net Income(TTM)-58.01M
Analysts84.44
Price Target18.02 (40.78%)
Short Float %1.52%
Short Ratio0.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-59.55%
Min EPS beat(2)-139.84%
Max EPS beat(2)20.75%
EPS beat(4)2
Avg EPS beat(4)-33.67%
Min EPS beat(4)-139.84%
Max EPS beat(4)20.75%
EPS beat(8)3
Avg EPS beat(8)-27.3%
EPS beat(12)6
Avg EPS beat(12)-15.42%
EPS beat(16)8
Avg EPS beat(16)-11.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40.62%
EPS NY rev (1m)5.04%
EPS NY rev (3m)10.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-24.11
EYN/A
EPS(NY)-8.39
Fwd EYN/A
FCF(TTM)-18.25
FCFYN/A
OCF(TTM)-18.26
OCFYN/A
SpS0
BVpS8.82
TBVpS8.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.44%
ROE -245.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.01%
ROA(5y)-39.92%
ROE(3y)-61.74%
ROE(5y)-45.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -18.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.09%
Cap/Depr(5y)71.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.55%
EPS Next Y31.73%
EPS Next 2Y28.33%
EPS Next 3Y22.78%
EPS Next 5Y13.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.5%
OCF growth 3YN/A
OCF growth 5YN/A

NEXTCURE INC / NXTC FAQ

What is the ChartMill fundamental rating of NEXTCURE INC (NXTC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NXTC.


What is the valuation status of NEXTCURE INC (NXTC) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEXTCURE INC (NXTC). This can be considered as Overvalued.


What is the profitability of NXTC stock?

NEXTCURE INC (NXTC) has a profitability rating of 0 / 10.


What is the financial health of NEXTCURE INC (NXTC) stock?

The financial health rating of NEXTCURE INC (NXTC) is 5 / 10.